热门资讯> 正文
Chimerix GAAP每股收益为-0.25美元，低于0.01美元，收入为0.06万美元，差0.25万美元
2025-03-21 18:07
- Chimerix press release (NASDAQ:CMRX): Q4 GAAP EPS of -$0.25 beats by $0.01.
- Revenue of $57K (vs. $4K Y/Y) misses by $0.25M.
- Chimerix’s balance sheet at December 31, 2024 included $140.1 million of capital available to fund operations, no outstanding debt, and approximately 92.2 million outstanding shares of common stock.
- Chimerix’s balance sheet at December 31, 2024 included $140.1 million of capital available to fund operations, no outstanding debt, and approximately 92.2 million outstanding shares of common stock.
More on Chimerix
- Jazz Buys Chimerix - A Good Deal To Make With Major Approval Catalyst In Play
- Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients
- Chimerix gains on FDA priority review for brain tumor drug
- Biggest stock movers Tuesday: INTC, DAL, STZ, HEES, and more
- Seeking Alpha’s Quant Rating on Chimerix
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
